Perspective Therapeutics Announces Acceptance of [212Pb]VMT01 Data for Presentation at SITC 2026

Patients in the previously presented interim analysis had received a median of 4 prior lines of systemic therapy.

Rhea-AI Summary

Perspective Therapeutics (CATX) announced acceptance of its [212Pb]VMT01 melanoma program data for presentation at SITC’s annual meeting in November 2026. The phase I/IIa trial poster covers treatment alone and with nivolumab and is scheduled for November 6, 2026, in Phoenix.

Previously presented ASCO interim results, with a March 25, 2026 data cutoff, included two responders among seven patients in the 3.0 mCi monotherapy cohort. Six patients (86%) had stable disease or a partial response. Across 27 treated patients, eight (30%) experienced Grade 3 treatment-emergent adverse events. There were no dose-limiting toxicities, adverse-event-related discontinuations, or Grade 4 or Grade 5 treatment-emergent adverse events.

Positive

• Minor pointThe 3.0 mCi monotherapy cohort had two responders among seven treated patients, including one newly observed early response.
• Minor pointStable disease or partial response occurred in six patients (86%) in the seven-patient 3.0 mCi monotherapy cohort.
• Minor pointFour patients completed all three treatments with at least 24 weeks of follow-up; two remained on treatment.
• Minor pointSafety findings included no dose-limiting toxicities, adverse-event-related discontinuations, or Grade 4 or Grade 5 treatment-emergent adverse events.

Negative

• Minor pointEight of 27 treated patients (30%) experienced Grade 3 treatment-emergent adverse events in the ASCO interim analysis.

Key Terms

mc1r, open-label, dose escalation, dose expansion, +2 more

6 terms

mc1r medical

"with nivolumab in participants with previously treated unresectable or metastatic melanoma"

MC1R is a human gene that encodes a protein on cell surfaces involved in skin and hair pigmentation and in cellular responses to ultraviolet light. For investors, changes or mutations in MC1R matter because they can influence disease risk (notably certain skin cancers), be used as biomarkers, or serve as targets for diagnostics and therapies—think of it as a control switch that drug developers or diagnostic companies might aim to measure or modify.

open-label medical

"multi-center, open-label dose escalation, dose expansion study"

Open-label describes a situation where everyone involved in a study or process knows the full details, such as who is receiving a treatment or intervention. For investors, understanding whether a project or product is open-label helps gauge the level of transparency and potential biases, influencing trust and decision-making. It’s like knowing whether a test or experiment is conducted openly or behind closed doors.

dose escalation medical

"open-label dose escalation, dose expansion study"

Dose escalation is the process of gradually increasing the amount of a treatment or substance over time. In finance, it can refer to slowly raising investments or commitments to manage risk and assess performance. For investors, understanding dose escalation helps gauge how companies or strategies adjust their approaches, which can impact future growth or stability.

dose expansion medical

"dose escalation, dose expansion study"

Dose expansion is a stage in drug testing where researchers give a selected dose or small set of doses to a larger group of participants to confirm safety and look for signs of benefit. Think of it like deciding which recipe version tastes best and then serving it to more people to see if the result holds up. For investors, dose expansion generates broader safety and early-effectiveness data that can reduce risk, inform pricing of later trials, and influence regulatory or partnership decisions.

dose limiting toxicities medical

"no dose limiting toxicities (DLTs), no discontinuations due to adverse events"

A dose limiting toxicity is a harmful side effect observed during a drug trial that is severe enough to prevent increasing the dose further. Think of it as the safety red line that tells researchers they’ve reached the highest tolerable amount of a drug; it matters to investors because these limits shape dosing, affect whether a drug can be effective, influence trial costs and timelines, and often change the likelihood of eventual regulatory approval and commercial success.

treatment emergent adverse events medical

"no Grade 4 or Grade 5 treatment emergent adverse events (TEAEs)"

Treatment emergent adverse events are any new or worsened medical problems that appear after a patient starts a drug or medical intervention during a clinical trial. Investors care because the number, severity, and frequency of these events influence safety profiles, regulatory approval chances, and market acceptance; think of them like unexpected problems that crop up after installing a software update—minor ones may be manageable, but serious or common issues can stall or derail the product.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEATTLE, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that data from the Company’s lapemelanotide zapixetar (also known as [²¹²Pb]VMT01) program have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting & Pre-Conference Programs taking place November 4 to 8, 2026, in Phoenix, Arizona. SITC plans to release further details for regular abstracts on November 3, 2026.

Presenting Author	Abstract Title	Presentation Details
Matthew Block, Department of Oncology, Mayo Clinic	A phase I/IIa trial of [212Pb]VMT01 MC1R-targeted alpha-particle mono- and combination-therapy with nivolumab in participants with previously treated unresectable or metastatic melanoma	Abstract Number: 571 Presentation type: Poster presentation Date: Friday, Nov. 6, 2026 Location: PCC-North Building-Lower Level-Exhibition Halls 4-5-6

About [²¹²Pb]VMT-01

Perspective designed [²¹²Pb]VMT01 to target and deliver ²¹²Pb to metastatic melanoma tumor sites expressing MC1R, a protein that can be overexpressed in metastatic melanoma tumors.¹ The Company is conducting a multi-center, open-label dose escalation, dose expansion study (clinicaltrials.gov identifier NCT05655312) in patients with histologically confirmed melanoma and MC1R-positive imaging scans.

Interim analysis with a data cut-off date of March 25, 2026 was presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in May 2026. Highlights from the ASCO analysis included the following:

• Patients were heavily pre-treated prior to entering trial with a median of 4 prior lines of systemic therapy (including prior checkpoint inhibitors)
  
  
• One new response was observed early in the 3.0 mCi monotherapy cohort, in addition to a previously reported response, for a total of two responders out of seven treated patients
  
  
• Six patients (86%) experienced stable disease or partial response out of the seven patients in the 3.0 mCi monotherapy cohort; four patients completed all three treatments with 24 weeks or more of follow-up since their first treatment, and two remained on treatment and in study
• [²¹²Pb]VMT01 was well-tolerated with no dose limiting toxicities (DLTs), no discontinuations due to adverse events, and no Grade 4 or Grade 5 treatment emergent adverse events (TEAEs)
• Eight (30%) patients out of a total of 27 patients treated experienced Grade 3 TEAEs

About Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc. is a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-generating isotope ²¹²Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging techniques that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables visualization of the specific tumor and subsequent treatment, potentially improving efficacy and minimizing toxicity.

The Company is advancing a portfolio of clinical-stage programs in the U.S., including bamzireotide navoxetan (VMT-α-NET, neuroendocrine tumors), lapemelanotide zapixetar (VMT01, melanoma), and PSV359 (solid tumors).

The Company is expanding its regional finished drug product candidate supply network, enabled by its proprietary ²²⁴Ra/²¹²Pb generator platform used to manufacture clinical drug product candidates, to support the delivery of patient-ready drug product candidates for clinical trials and, if approved, commercial operations.

For more information, please visit the Company's website at www.perspectivetherapeutics.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Words such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "estimate," "believe," "predict," "potential," or "continue" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements concerning, among other things, the Company’s clinical development plans and the expected timing for the release of additional data from its clinical programs; the Company’s regional distribution and manufacturing capabilities; and other statements that are not historical fact.

The Company may not actually achieve the plans, intentions, or expectations disclosed in the forward-looking statements, and you should not place undue reliance on the forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Known risk factors include that the Company’s preclinical development plans and clinical trials may be more costly or take longer to complete than anticipated, or may never be completed, or may not generate results that warrant future development of the tested product candidate; the Company may elect to change its strategy regarding its product candidates and development activities; economic and market conditions may worsen; regulatory agencies may issue decisions that negatively impact the Company’s product candidates and clinical development plans; and risks related to the sufficiency of the Company’s cash resources for its future operating expenses and capital expenditures. A more complete discussion of the risks and uncertainties facing the Company appears under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”), in the Company’s other filings with the SEC, and in the Company’s future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Media and Investor Relations Contacts:

Perspective Therapeutics IR:
Annie J. Cheng, CFA
ir@perspectivetherapeutics.com

ENTENTE Network of Companies
Katie Morris, PhD
katiemorris@ententeinc.com

---

¹ Su DG, Djureinovic D, Schoenfeld D, et al. Melanocortin-1 Receptor Expression as a Marker of Progression in Melanoma. JCO Precis Oncol. 2024;8:e2300702. doi:10.1200/PO.23.00702.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Perspective Therapeutics present its VMT01 data at SITC 2026?

The VMT01 poster presentation is scheduled for November 6, 2026, at SITC in Phoenix. Abstract 571 covers the phase I/IIa trial of treatment alone and in combination with nivolumab in previously treated unresectable or metastatic melanoma.

Who is eligible for Perspective Therapeutics’ VMT01 clinical study?

The study enrolls patients with histologically confirmed melanoma and MC1R-positive imaging scans. It is a multicenter, open-label study evaluating escalating doses and expanded patient cohorts, registered as NCT05655312. MC1R is a protein that can be overexpressed in metastatic melanoma tumors.